SkipNav
Quality Measures
YNHH

Quality Measures

Outcomes Reporting

Patients face an increasingly complex decision when deciding where to go for their cancer treatment. There are several factors that can aid in that decision-making process including location, center designation, physician experience, physician referral, health plan coverage, and options for treatment. In addition to these factors, nationally accepted quality measures, outcome data, and patient satisfaction information can also be helpful tools in comparisons between cancer treatment centers or hospitals.

ACSO/NCCN Quality Measures

Smilow Cancer Hospital at Yale-New Haven and Yale Cancer Center acknowledge the seven American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) evidence-based quality guidelines for breast and colorectal cancers. The latest performance data for the Breast Cancer Program and Gastrointestinal Cancers Program in the treatment of these diseases is listed below.

Colorectal Cancer Performance Rates

Performance Measure 4 5 6 7 8
Adjuvant Chemotherapy (C/CT)1 80% 88% 73% 88% %
12 Regional Lymph Nodes
(C/12RLN)2
89% 88% 90% 91% 95%
Adjuvant Radiation Therapy (R/RT)3 % 80% 83% % %
Postoperative Adjuvant Chemotherapy Therapy (R/CT)4 - - 50% 89% 88%
  1. Adjuvant chemotherapy is considered or administered within 4 months of diagnosis for patients under the age of 80 with stage III (lymph node positive) colon cancer.
  2. At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.
  3. Radiation therapy is considered or administered within 6 months of diagnosis for patients under the age of 80 with clinical or pathologic T4N1M0 or stage III colorectal cancer after receiving surgical resection for rectal cancer.
  4. Postoperative adjuvant chemotherapy is administered within 9 months (270 days) of diagnosis to patients under the age of 80 with clinical or pathologic AJCC Stage II or Stage III receiving surgical resection for rectal cancer.

NMDP Allogeneic Bone Marrow Transplant Center Data

The National Marrow Donor Program tracks data on patients who have received a transplant at accredited United States Transplant Centers. Yale Cancer Center's actual results are above the predicted survival range. The following chart shows how Yale Cancer Center compares to Transplant Centers in the United States reporting more than 50 allogeneic transplants during the most recent reporting period (2004 - 2008):

Transplant Centers Comparison Chart

Institution # of Patients One-Year Survival Predicted Survival
Yale University/Yale-New Haven Hospital 107 73% 63%
B 115 74% 58%
C 530 68% 58%
D 149 68% 59%
E 455 66% 58%
F 334 66% 65%
G 118 66% 55%
H 283 65% 63%
I 218 64% 62%
J 228 64% 53%
K 83 64% 58%
L 198 63% 58%
M 154 62% 61%
N 115 62% 60%
O 94 62% 66%
P 102 61% 62%
Q 674 60% 59%
R 351 60% 57%
S 160 60% 58%
T 724 59% 54%
U 125 59% 62%
V 72 59% 58%
W 263 58% 59%
X 210 58% 58%
Y 224 57% 59%
Z 162 56% 53%
AA 149 56% 57%
BB 81 56% 54%
CC 269 55% 54%
DD 146 55% 60%
EE 148 54% 56%
FF 93 54% 56%
GG 332 53% 50%
HH 184 53% 57%
II 75 53% 58%
JJ 65 52% 48%
KK 294 51% 54%
LL 147 51% 54%
MM   51% 55%
NN 70 51% 59%
OO 139 50% 58%
PP 118 50% 55%
QQ 81 49% 61%
RR 126 48% 47%
SS 72 48% 58%
TT 103 47% 57%
UU 96 46% 51%
VV 84 43% 52%
WW 142 42% 53%
XX 132 42% 53%
YY 90 36% 42%

*based on overall disease condition of treated patients, measured on a scale from 1 (low risk) to 5 (high risk).

Our Physicians

Use our online tool to find a doctor

Yale Cancer Center
Magnet Recognition Best Hospitals 2012-2013
Visit Closer to Free